{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:25:12Z","timestamp":1748453112594},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Australian harm reduction services are provided via a mix of modalities, including fixed-site needle and syringe programmes (NSP) and syringe-dispensing machines (SDMs). SDMs are cost-effective and provide 24-h anonymous access to needles\/syringes, often to underserved geographic areas, and can attract clientele who may choose not to use NSPs. The introduction of COVID-19 control measures saw disruptions and adaptations to the provision of harm reduction services. It is possible that SDMs filled the gap in otherwise disrupted harm reduction services in Melbourne. In this paper, we use data from four SDMs and an NSP to explore changes to harm reduction usage during periods of COVID-19 lockdowns in Melbourne, Australia, in 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our data span September 2017\u2013December 2020. We analysed daily counts of SDM use and monthly counts of NSP use, according to unique presentations to both. Auto-regressive integrated moving average (ARIMA) time-series models were fitted to the data with the effects of lockdowns estimated via a step function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Across the study period, we estimated 85,851 SDM presentations and 29,051 NSP presentations. Usage across both the SDMs and the NSP declined during the COVID-19 lockdowns, but only the decline in SDM usage was significant in ARIMA analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The slight, but significant decline in SDM use suggests barriers to access, though this may have been mitigated by SDM users acquiring needles\/syringes from other sources. The decline, however, may be a concern if it led to lowered needle\/syringe coverage and a subsequent increase in injecting risk. Further work is needed to properly explore potential changes in preference for needle\/syringe acquisition site and associated barriers. Importantly, this work adds to the body of literature around the impacts of COVID-19 on harm reduction provision and potential areas of improvement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00683-9","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:05:30Z","timestamp":1662548730000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Time-series analysis of presentations to four syringe dispensing machines and a needle and syringe programme during COVID-19 lockdowns in Melbourne, Australia"],"prefix":"10.1186","volume":"19","author":[{"given":"Daniel","family":"O\u2019Keefe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reece D.","family":"Cossar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jacka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"12","key":"683_CR1","doi-asserted-by":"publisher","first-page":"E1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):E1208\u201320.","journal-title":"Lancet Glob Health"},{"key":"683_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2471\/BLT.18.224089","volume":"97","author":"D O'Keefe","year":"2019","unstructured":"O\u2019Keefe D, Bluthenthal RN, Kral A, Aitken C, McCormack A, Dietze P. Measures of harm reduction service provision for people who inject drugs. Bull World Health Organ. 2019;97:605\u201311.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"683_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1024\/0939-5911\/a000641","volume":"66","author":"D O'Keefe","year":"2020","unstructured":"O\u2019Keefe D, Ritter A, Stoove M, Hughes C, Dietze P. Harm reduction programs and policy in Australia: barriers and enablers to effective implementation. SUCHT. 2020;66(1):33\u201343.","journal-title":"SUCHT"},{"key":"683_CR4","unstructured":"Harm Reduction International. Global state of harm reduction 2020. London: Harm Reduction International; 2020."},{"key":"683_CR5","volume-title":"Needle syringe program national minimum data collection: national data report 2021","author":"S Heard","year":"2021","unstructured":"Heard S, Iversen J, Geddes L, Kwon J, Maher L. Needle syringe program national minimum data collection: national data report 2021. Sydney: Kirby Institute, UNSW Sydney; 2021."},{"issue":"6","key":"683_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.15288\/jsad.2021.82.752","volume":"82","author":"D Otiashvili","year":"2021","unstructured":"Otiashvili D, Kirtadze I, Mgebrishvili T, Beselia A, Tabatadze M, Otiashvili N, et al. Smart syringe vending machines: research capabilities and implications for research data collection. J Stud Alcohol Drugs. 2021;82(6):752\u20137.","journal-title":"J Stud Alcohol Drugs"},{"issue":"6","key":"683_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.drugpo.2007.07.006","volume":"19","author":"MM Islam","year":"2008","unstructured":"Islam MM, Wodak A, Conigrave KM. The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings. Int J Drug Policy. 2008;19(6):436\u201341.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"683_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.drugpo.2008.06.004","volume":"20","author":"D McDonald","year":"2009","unstructured":"McDonald D. The evaluation of a trial of syringe vending machines in Canberra, Australia. Int J Drug Policy. 2009;20(4):336\u20139.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"683_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14659890701249640","volume":"12","author":"MM Islam","year":"2009","unstructured":"Islam MM, Conigrave KM. Syringe vending machines as a form of needle syringe programme: advantages and disadvantages. J Subst Use. 2009;12(3):203\u201312.","journal-title":"J Subst Use"},{"issue":"1","key":"683_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3109\/09687630802067251","volume":"17","author":"C Treloar","year":"2010","unstructured":"Treloar C, Hopwood M, Bryant J. \u2018Does anyone know where to get fits from around here?\u2019 policy implications for the provision of sterile injecting equipment through pharmacies in Sydney, Australia. Drugs Educ Prev Policy. 2010;17(1):72\u201383.","journal-title":"Drugs Educ Prev Policy"},{"key":"683_CR11","volume-title":"Trends in, and characteristics associated with, trouble accessing sterile needles and syringes among people who inject drugs in Sydney, New South Wales","author":"U Chandrasena","year":"2021","unstructured":"Chandrasena U, Price O, Sutherland R. Trends in, and characteristics associated with, trouble accessing sterile needles and syringes among people who inject drugs in Sydney, New South Wales. Sydney: NDARC, University of NSW; 2021."},{"issue":"1","key":"683_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-020-00370-7","volume":"17","author":"A Dunlop","year":"2020","unstructured":"Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):1\u20137.","journal-title":"Harm Reduct J"},{"issue":"7","key":"683_CR13","doi-asserted-by":"publisher","first-page":"e0253510","DOI":"10.1371\/journal.pone.0253510","volume":"16","author":"N Scott","year":"2021","unstructured":"Scott N, Saul A, Spelman T, Stoove M, Pedrana A, Saeri A, et al. The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city. PLoS ONE. 2021;16(7):e0253510.","journal-title":"PLoS ONE"},{"issue":"3","key":"683_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/00048658211007532","volume":"54","author":"CT Langfield","year":"2021","unstructured":"Langfield CT, Payne JL, Makkai T. Drug offence detection during the pandemic: an ARIMA analysis of rates and regional differences in Queensland. Aust J Criminol. 2021;54(3):344\u201364.","journal-title":"Aust J Criminol"},{"key":"683_CR15","unstructured":"Victorian Department of Health and Human Services. Needle and syringe program information system (NSPIS) 2015. Available from: https:\/\/www.health.vic.gov.au\/funding-and-reporting-aod-services\/needle-and-syringe-program-information-system-nspis."},{"key":"683_CR16","volume-title":"Melbourne marks 200 days of COVID-19 lockdowns since the pandemic began","author":"J Dunstan","year":"2021","unstructured":"Dunstan J. Melbourne marks 200 days of COVID-19 lockdowns since the pandemic began. Sydney: ABC News; 2021."},{"key":"683_CR17","volume-title":"Australian drug trends 2020: key findings from the national illicit drug reporting system (IDRS) interviews","author":"A Peacock","year":"2020","unstructured":"Peacock A, Uporova J, Karlsson A, Price O, Gibbs D, Swanton R, et al. Australian drug trends 2020: key findings from the national illicit drug reporting system (IDRS) interviews. Sydney: NDARC, University of NSW; 2020."},{"issue":"6","key":"683_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3109\/09687637.2014.956051","volume":"21","author":"E Cama","year":"2014","unstructured":"Cama E, Brener L, Bryant J. Characteristics and attendance patterns of a fixedsite NSP and nearby SVM: The benefits of 24-hour access to sterile injecting equipment. Drugs Educ Prev Policy. 2014;21(6):476\u201381.","journal-title":"Drugs Educ Prev Policy"},{"key":"683_CR19","volume-title":"The admit study: linking people who use automatic needle\/syringe dispensing machines with hepatitis C care","author":"H Coupland","year":"2021","unstructured":"Coupland H, Day C. The admit study: linking people who use automatic needle\/syringe dispensing machines with hepatitis C care. Sydney: Sydney Local Health District; 2021."},{"key":"683_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/dar.13079","volume":"39","author":"P Dietze","year":"2020","unstructured":"Dietze P, Peacock A. Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: anticipated consequences and initial responses. Drug Alcohol Rev. 2020;39:297\u2013300.","journal-title":"Drug Alcohol Rev"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00683-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T22:04:32Z","timestamp":1662588272000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00683-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PD is supported by NHMRC Research Fellowships (#1136908). PD has received Investigator-Initiated Research funding from Gilead Sciences and an untied educational grant from Indivior unrelated to this study. PD has served as an unpaid member of an advisory board for an intranasal naloxone product. All other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}